CDC shooting suspect died of self-inflicted gunshot: Officials
The Georgia man suspected of opening fire on Centers for Disease Control buildings near Emory University, killing one police officer, died of a self-inflicted gunshot wound and expressed "discontent" with COVID-19 vaccines, authorities said.
Hundreds of shell casings were discovered at the scene of the shooting, which broke out the afternoon of Aug. 8 in Atlanta, according to Georgia Bureau of Investigation Director Chris Hosey. Nearly 200 bullets struck six different CDC buildings, Hosey said in an update on Aug. 12.
The suspect, identified over the weekend as 30-year-old Patrick Joseph White, was found dead on the second floor of a building that included a CVS store. It was later determined that his fatal gunshot wound was self-inflicted.
White was on law enforcement's radar weeks before the shooting because he had expressed suicidal ideation, prompting contact with law enforcement. He had no known criminal history, Hosey said.
DeKalb County Police Officer David Rose, a 33-year-old husband and father of two with another child on the way, was killed by one of the shooter's weapons, Hosey said.
"He served with honor, courage and unwavering dedication. His sacrifice will never be forgotten, and his commitment to protecting others is a profound testament to the very best of the law enforcement profession," Hosey said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
One in four US adults with diabetes used a GLP-1 drug last year, survey finds
By Bhanvi Satija (Reuters) -More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United States for treating type 2 diabetes. They are sold as Zepbound and Wegovy, respectively, for weight loss and are being tested for other conditions. Use of the injectable drugs was highest among adults with diabetes aged 50–64 at 33.3%, reflecting the more significant disease burden in this group, the report said. A quarter or 25.3% of adults with diabetes aged 18 to 34 reported using a GLP-1 drug, while the adoption rate was 20.8% among those 65 and older. The data are from a nationally representative annual survey of U.S. adults aged 18 and older that was conducted in person and with follow-up by phone in 2024. In 2024, for the first time, participants in the annual survey who had diabetes were asked if they were using the Lilly or Novo blockbusters or other GLP-1 drugs to lower blood sugar or lose weight. The drugs mimic the activity of a hormone that regulates blood sugar levels, slows digestion and helps people feel full for longer. Drugmakers Lilly and Novo have faced criticism about the cost of the treatments, which carry a list price of about $1,000 for a month's supply. Roughly 31% of survey participants who reported using insulin also reported using GLP-1 drugs, as did about 28% of patients who were using oral drugs to control their blood sugar, according to the report, indicating that these treatments are being integrated into combination regimens. Hispanic adults with diabetes had the highest rate of GLP-1 use, at 31.3%, followed by Black non-Hispanic and White non-Hispanic adults, at 26.5% and 26.2%, respectively, the survey found. Only 12.1% of Asian non-Hispanic adults with diabetes used the drugs, which may reflect disparities in access or adoption of the therapies. Solve the daily Crossword
San Francisco Chronicle
8 minutes ago
- San Francisco Chronicle
Man accused of faking his death to avoid rape charges is found guilty of sexual assault in Utah
SALT LAKE CITY (AP) — A Rhode Island man accused of faking his death and fleeing the United States to evade rape charges was found guilty Wednesday of sexually assaulting a former girlfriend in his first of two Utah trials. A jury in Salt Lake County found Nicholas Rossi guilty of a 2008 rape after a three-day trial in which his accuser and her parents took the stand. The verdict came hours after Rossi, 38, declined to testify on his own behalf. He will be sentenced in the case on Oct. 20 and is set to stand trial in September for another rape charge in Utah County. An obituary published online claimed Rossi had died on Feb. 29, 2020, of late-stage non-Hodgkin lymphoma. But police in his home state of Rhode Island, along with his former lawyer and a former foster family, cast doubt on whether he was dead. He was arrested in Scotland the following year while receiving treatment for COVID-19 after hospital staff in Glasgow recognized his distinctive tattoos from an Interpol notice. He was extradited to Utah in January 2024 after losing an extradition appeal in which he claimed he was an Irish orphan named Arthur Knight who was being framed.
Time Business News
14 minutes ago
- Time Business News
Hygiene Tech Meets Healing Proteins
Hospital-acquired infections can be caused by the cross-infection from surface and skin of patient, equipment, and healthcare staff. Various types of products and services are available to control hospital-acquired infections such as sterilization, cleaning & disinfection products, protective barriers, and endoscope reprocessing products. Increase in awareness regarding personal hygiene after COVID-19 is a major factor to boost the Hospital Infection Prevention and Control growth. Growth factors, proteins or peptides found in nature, are important for the control of cell actions like growth, specialization, movement, and survival. They attach to certain receptors on cell surfaces, which starts signals inside the cells that change how they act. Growth factors are needed for body functions such as development in embryos, healing wounds, fixing tissues, and immune reactions. Key Growth Drivers and Opportunities High Cases of Hospital Acquired Infections: Hospital-acquired infections (HAIs) remain a major risk to patient safety and healthcare results around the world. These infections, often caused by bacteria like Staphylococcus aureus, Clostridium difficile, and Escherichia coli, usually happen because of long hospital stays, surgeries, poor infection control, and antibiotic resistance. Those in intensive care, people with weak immune systems, and those having surgery are at risk. HAIs raise sickness and death rates; these also cause higher medical costs and longer stays in hospitals. Growing Geriatric Population: The growing geriatric population significantly contributes to the rise in hospital-acquired infections, as older adults often have weakened immune systems and require frequent medical care or hospitalization. This increases their vulnerability to infections, driving the demand for effective hospital infection prevention and control measures. As a result, healthcare facilities are investing more in disinfection, protective equipment, and sterilization solutions to ensure patient safety and reduce infection risks in aging populations. Challenges Failure of end-users to follow infection prevention rules limits how well hospital infection control works. When staff, patients, or support people don't follow hygiene rules—such as washing hands, sterilizing tools, or using safety gear— the risk of contamination and infections rises. Innovation and Expansion NAVTA & Virox Launch Free Infection Control Training for Safer Vet Care In March 2023, (National Association of Veterinary Technicians in America) NAVTA, Virox launch certificate program in infection prevention, to advance best practices in infection prevention. This program is a free online program designed to provide professionals with the knowledge needed to reduce the risk of spreading infection and create a safer workplace for their team, patients, and clients. NeoIPC Unveils Toolkit to Shield Newborns from Hospital Infections In November 2023, The NeoIPC Consortium announced the launch of a new surveillance toolkit to help neonatal intensive care units (NICUs) track and prevent hospital-acquired infections (HAIs) in high-risk newborns, including very preterm infants. This toolkit aims to standardize how infections are tracked in Newborn Intensive Care Units (NICUs) to allow for improved data gathering and assessment. It has tools, training, and reporting forms made for newborn care locations. By helping with early detection and response, this project hopes to lower infection rates and improve results for fragile newborns. Inventive Sparks, Expanding Markets The key players operating the hospital infection prevention and control market includes, 3M Company, Crosstex International, Inc., Johnson & Johnson, Belimed AG, among others. Worldwide business aims center on encouraging lasting growth, improving health and safety for the public, and boosting progress through cooperation. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
